PT  - JOURNAL ARTICLE
AU  - Biondi, Mia J.
AU  - Estes, Chris
AU  - Razavi-Shearer, Devin
AU  - Sahdra, Kanwar
AU  - Lipton, Nechama
AU  - Shah, Hemant
AU  - Capraru, Camelia
AU  - Janssen, Harry L.A.
AU  - Razavi, Homie
AU  - Feld, Jordan J.
TI  - Cost-effectiveness modelling of birth and infant dose vaccination against hepatitis B virus in Ontario from 2020 to 2050
AID  - 10.9778/cmajo.20210284
DP  - 2023 Jan 01
TA  - CMAJ Open
PG  - E24--E32
VI  - 11
IP  - 1
4099  - http://www.cmajopen.ca/content/11/1/E24.short
4100  - http://www.cmajopen.ca/content/11/1/E24.full
SO  - CMAJ2023 Jan 01; 11
AB  - Background: The World Health Organization recommends universal birth dose vaccination for hepatitis B virus (HBV), yet only 3 provinces and territories in Canada provide birth dose vaccination, and Canadian-born children in Ontario are acquiring HBV before adolescent vaccination. We sought to determine whether birth and/or infant HBV vaccination is cost-effective.Methods: We used a dynamic HBV model that incorporates population by year, disease stage, sex and the influence of immigration to quantify the disease and economic burden of chronic HBV infection in Ontario from 2020 to 2050. We compared 4 vaccination scenarios, which included a birth dose vaccine and variations of the 2 subsequent doses (either alone or as a part of the hexavalent vaccine) and a hexavalent-only strategy in infancy with the current adolescent vaccination strategy. Our costing estimates were based on values from 2020.Results: All 4 infant vaccination approaches prevented an additional 550–560 acute and 160 chronic pediatric HBV infections from 2020 to 2050 compared with adolescent vaccination. Whereas birth dose could be cost-effective, incorporating vaccination into a hexavalent vaccine was cost saving. By 2050, the hexavalent approach led to $428 000 in cost savings per disability-adjusted life years averted.Interpretation: At the current prevalence in Ontario, a switch to birth dose or infant dose will be cost-effective or even cost saving. Introducing any form of infant HBV immunization in Ontario will prevent acute and chronic pediatric HBV infections.